- Home
- ELS vs RPRX Comparison
ELS vs RPRX Comparison
Compare ELS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELS
- RPRX
- Stock Information
- Founded
- ELS 1992
- RPRX 1996
- Country
- ELS United States
- RPRX United States
- Employees
- ELS N/A
- RPRX N/A
- Industry
- ELS Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ELS Real Estate
- RPRX Health Care
- Exchange
- ELS Nasdaq
- RPRX Nasdaq
- Market Cap
- ELS 12.4B
- RPRX 14.2B
- IPO Year
- ELS 1993
- RPRX 2020
- Fundamental
- Price
- ELS $64.32
- RPRX $33.15
- Analyst Decision
- ELS Buy
- RPRX Strong Buy
- Analyst Count
- ELS 9
- RPRX 4
- Target Price
- ELS $74.33
- RPRX $42.50
- AVG Volume (30 Days)
- ELS 1.4M
- RPRX 3.7M
- Earning Date
- ELS 04-21-2025
- RPRX 05-08-2025
- Dividend Yield
- ELS 3.09%
- RPRX 2.65%
- EPS Growth
- ELS 5.86
- RPRX 37.42
- EPS
- ELS 1.94
- RPRX 2.45
- Revenue
- ELS $1,537,798,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- ELS $2.78
- RPRX $31.30
- Revenue Next Year
- ELS $3.87
- RPRX $5.82
- P/E Ratio
- ELS $33.16
- RPRX $13.54
- Revenue Growth
- ELS 1.94
- RPRX 1.12
- 52 Week Low
- ELS $58.86
- RPRX $24.05
- 52 Week High
- ELS $76.60
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- ELS 47.81
- RPRX 57.43
- Support Level
- ELS $63.55
- RPRX $31.97
- Resistance Level
- ELS $65.23
- RPRX $34.11
- Average True Range (ATR)
- ELS 1.37
- RPRX 0.71
- MACD
- ELS 0.10
- RPRX 0.09
- Stochastic Oscillator
- ELS 63.25
- RPRX 62.06
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.